松岡 宏

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Rectal Neoplasms 64%
3. Fluorouracil 60%
4. Drug Therapy 49%
5. Neoplasm Metastasis 37%
6. Neoplasms 36%
7. Thymidylate Synthase 32%
8. XELOX 31%
9. Liver 26%
10. Robotics 23%
11. Oxaliplatin 23%
12. Sigmoid Neoplasms 22%
13. Prolapse 21%
14. Chemoradiotherapy 21%
15. Bevacizumab 20%
16. Colonic Neoplasms 19%
17. Japan 17%
18. Irinotecan 16%
19. Paraffin 14%
20. Rectum 13%
21. Progression-Free Survival 13%
22. Leucovorin 12%
23. Capecitabine 12%
24. Therapeutics 11%
25. Squamous Cell Carcinoma 11%
26. Stomach Neoplasms 11%
27. Orotate Phosphoribosyltransferase 10%
28. Transanal Endoscopic Surgery 10%
29. Pelvis 10%
30. Monoclonal Antibodies 10%
31. Lymph Node Excision 10%
32. Organic Cation Transporter 2 10%
33. Organic Cation Transporter 1 10%
34. thymidine kinase 1 10%
35. Hypersensitivity 9%
36. Recurrence 9%
37. Retrospective Studies 9%
38. Colostomy 9%
39. Cohort Studies 9%
40. Rectovaginal Fistula 9%
41. Nonprofit Organizations 9%
42. Rectocele 9%
43. Dihydrouracil Dehydrogenase (NADP) 9%
44. Formaldehyde 9%
45. Panitumumab 8%
46. Nivolumab 8%
47. Solitary Fibrous Tumors 8%
48. Cyclin-Dependent Kinase 4 8%
49. Survival 8%
50. Persistent Vegetative State 8%